JP2022514949A5 - - Google Patents

Info

Publication number
JP2022514949A5
JP2022514949A5 JP2021536363A JP2021536363A JP2022514949A5 JP 2022514949 A5 JP2022514949 A5 JP 2022514949A5 JP 2021536363 A JP2021536363 A JP 2021536363A JP 2021536363 A JP2021536363 A JP 2021536363A JP 2022514949 A5 JP2022514949 A5 JP 2022514949A5
Authority
JP
Japan
Prior art keywords
hydrocarbons
aliphatic
hydrogen
combinations
halogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536363A
Other languages
English (en)
Japanese (ja)
Other versions
JP7591503B2 (ja
JP2022514949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067914 external-priority patent/WO2020132483A1/en
Publication of JP2022514949A publication Critical patent/JP2022514949A/ja
Publication of JP2022514949A5 publication Critical patent/JP2022514949A5/ja
Priority to JP2024199936A priority Critical patent/JP7751054B2/ja
Application granted granted Critical
Publication of JP7591503B2 publication Critical patent/JP7591503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536363A 2018-12-21 2019-12-20 リファマイシンアナログおよびその抗体薬物コンジュゲート Active JP7591503B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199936A JP7751054B2 (ja) 2018-12-21 2024-11-15 リファマイシンアナログおよびその抗体薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862783506P 2018-12-21 2018-12-21
US62/783,506 2018-12-21
US201962844860P 2019-05-08 2019-05-08
US62/844,860 2019-05-08
PCT/US2019/067914 WO2020132483A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199936A Division JP7751054B2 (ja) 2018-12-21 2024-11-15 リファマイシンアナログおよびその抗体薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2022514949A JP2022514949A (ja) 2022-02-16
JP2022514949A5 true JP2022514949A5 (cg-RX-API-DMAC7.html) 2022-12-27
JP7591503B2 JP7591503B2 (ja) 2024-11-28

Family

ID=69326667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536363A Active JP7591503B2 (ja) 2018-12-21 2019-12-20 リファマイシンアナログおよびその抗体薬物コンジュゲート
JP2024199936A Active JP7751054B2 (ja) 2018-12-21 2024-11-15 リファマイシンアナログおよびその抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199936A Active JP7751054B2 (ja) 2018-12-21 2024-11-15 リファマイシンアナログおよびその抗体薬物コンジュゲート

Country Status (18)

Country Link
US (2) US11666658B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897841A1 (cg-RX-API-DMAC7.html)
JP (2) JP7591503B2 (cg-RX-API-DMAC7.html)
KR (1) KR102876950B1 (cg-RX-API-DMAC7.html)
CN (2) CN120309630A (cg-RX-API-DMAC7.html)
AU (2) AU2019403404B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012233A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123607A1 (cg-RX-API-DMAC7.html)
CL (3) CL2021001644A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009396A2 (cg-RX-API-DMAC7.html)
IL (2) IL318210A (cg-RX-API-DMAC7.html)
MA (2) MA66057B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007524A (cg-RX-API-DMAC7.html)
MY (1) MY207057A (cg-RX-API-DMAC7.html)
NZ (1) NZ777641A (cg-RX-API-DMAC7.html)
PH (1) PH12021551476A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106658XA (cg-RX-API-DMAC7.html)
WO (1) WO2020132483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
BR112023019720A2 (pt) * 2021-03-26 2024-01-23 Regeneron Pharma Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit
CN117147824A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用
CN115057871B (zh) * 2022-08-17 2022-11-15 北京丹大生物技术有限公司 利福平半抗原衍生物、利福平完全抗原、利福平抗体及应用
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
CN119950541B (zh) * 2025-01-10 2025-11-21 中国人民解放军总医院第一医学中心 Msr1基因作为靶点在筛选脓毒症防治药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59231092A (ja) * 1983-06-11 1984-12-25 Kanebo Ltd フエノチアジン型リフアマイシンおよびその医薬用途
JPS6345282A (ja) * 1986-04-14 1988-02-26 Kanegafuchi Chem Ind Co Ltd アシル基及び置換アルキル基を有するリフアマイシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPH01207293A (ja) 1987-03-24 1989-08-21 Kanegafuchi Chem Ind Co Ltd 置換ベンゾキサジノリフアマイシン誘導体
JPH01175938A (ja) 1987-12-29 1989-07-12 Kanegafuchi Chem Ind Co Ltd ウイルス感染症治療剤
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US20080051805A1 (en) 2006-08-28 2008-02-28 Leonard Pinchuk Hair Follicle Coring Tool and System Based Thereon
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
NZ578851A (en) 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
FI3366705T3 (fi) 2012-09-12 2023-07-28 Genzyme Corp Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI632157B (zh) 2013-05-31 2018-08-11 建南德克公司 抗壁磷壁酸抗體(anti-wall teichoic acid antibodies)及結合物
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
KR20170086536A (ko) 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
BR112018014355A2 (pt) * 2016-03-04 2018-12-18 Genentech, Inc. processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
WO2019217591A1 (en) * 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
JP7365830B2 (ja) * 2019-09-17 2023-10-20 テルモ株式会社 医療器具および医療器具の製造方法

Similar Documents

Publication Publication Date Title
IL318210A (en) Rifampicin analogs and their antibody-drug conjugates
JP2022537158A5 (cg-RX-API-DMAC7.html)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
US11819553B2 (en) Glypican 3 antibodies and conjugates thereof
RU2586885C2 (ru) Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство
US20240216525A1 (en) Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties
TWI790996B (zh) 用於製備聚乙二醇化的藥物-連接劑及其中間體之方法
JP2022512778A5 (cg-RX-API-DMAC7.html)
TWI660741B (zh) 抗體藥物複合物及其製造方法
US20110097322A1 (en) Partially loaded antibodies and methods of their conjugation
EP3662933A1 (en) Cd48 antibodies and conjugates thereof
JP2021513990A5 (cg-RX-API-DMAC7.html)
KR20160142885A (ko) 친화성 약제 컨쥬게이트
WO2021067820A1 (en) Formulation of antibody-drug conjugate
JP2024526298A5 (cg-RX-API-DMAC7.html)
RU2018102358A (ru) Нацеленные конъюгаты ksp ингибиторов
TW202410920A (zh) 包括聚合物賦形劑之抗體生物醫藥調配物
WO2024235134A9 (zh) 具有靶向作用的偶联物及其制备方法和用途
KR910000179A (ko) Aids용 결합체 면역원
CN120957760A (zh) 抗体药物偶联物及其制备方法和用途
CN120957756A (zh) 稠环化合物及其制备方法和用途
CN120882429A (zh) 配体-药物缀合物
RU2025113325A (ru) Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака
KR20240016231A (ko) 신규 오리스타틴 전구약물
NZ807937A (en) Hydrophobic auristatin f compounds and conjugates thereof